Skip to main content

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Active, not recruiting · Phase 1, Phase 2 · NCT02677922

Conditions: Leukemia, Myeloid, Acute

At a glance

Research payments reported, 2025
$94,624
U.S. investigators named
3
Sites paid
3
Planned or actual enrollment
130

About the trial

Sponsor
Celgene
Tested
AG-120 (drug), Azacitidine (drug), AG-221 (drug)
Dates
Started 2016-06-03; completion 2026-09-30
Results posted
Yes

The purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2. to investigate the safety, tolerability, and efficacy of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitrate dehydrogenase (IDH) enzyme isoforms 1 or 2 mutations, respectively.

From ClinicalTrials.gov, last updated 2026-02-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $94,624 in research payments for this study in 2025 (3 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • The University of Chicago Kovler Diabetes Center $42,261
  • Ut MD Anderson Cancer Center $38,539
  • Lee Daeyeol Mms $13,824

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.